CoreyGillMDMS

Physician

Dr. Gill is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
205 S Front Street
Brady 3 Suite 3a
Harrisburg, PA 17104
Phone+1 717-231-8722

UPMC Medical Education (Harrisburg)Residency, Emergency Medicine, 2022 - 2025
Washington University/B-JH/SLCH ConsortiumResidency, Neurological Surgery, 2021 - 2022
Icahn School of Medicine at Mount SinaiClass of 2021, MD
Icahn School of Medicine at Mount SinaiMS in Clinical Research, 2021
Boston UniversityBS, Human Physiology, Magna Cum Laude, 2010 - 2014
Boston UniversityBA, Anthropology, Magna Cum Laude, 2010 - 2014

Dr. Harold Lamport Biomedical Research Prize Icahn School of Medicine at Mount Sinai, 2021
Neuro-Oncology Trainee Award AANS/CNS Joint Section on Tumors, 2020
Summer Student Investigator Award Icahn School of Medicine at Mount Sinai, 2017
Professional Contribution Award in Recognition of Outstanding Professional Potential Boston University, 2014
Research Excellence Award in Anthropology Boston University, 2014
Undergraduate Research Opportunity Program Boston University, 2013
Summer Student Fellowship Massachusetts General Hospital and Harvard Medical School, 2012
Join now to see all

PubMed

6 citations
ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas.
Danielle Chaluts, Jonathan T Dullea, Muhammad Ali, Vikram Vasan, Alex Devarajan
Journal of Cancer Research and Clinical Oncology. 2023-07-01
mutation associated with accelerated time to recurrence for older patients with atypical meningiomas.
Jonathan T Dullea, Danielle Chaluts, Vikram Vasan, John W Rutland, Corey M Gill
British Journal of Neurosurgery. 2023-04-25
3 citations
NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.
Vikram Vasan, Jonathan T Dullea, Alex Devarajan, Muhammad Ali, John W Rutland
Journal of Neuro-Oncology. 2023-01-01